Intermittent treatment with the PARP inhibitor olaparib delays tumor development in BRCA1-deficient mice

被引：0
|
作者：
Liby, Karen T.
To, Ciric
机构：
来源：
CANCER RESEARCH | 2014年 / 74卷 / 23期
关键词：
D O I：
10.1158/1538-7445.CANSUSC14-30
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
30
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice
    To, Ciric
    Kim, Eun-Hee
    Royce, Darlene B.
    Williams, Charlotte R.
    Collins, Ryan M.
    Risingsong, Renee
    Sporn, Michael B.
    Liby, Karen T.
    CANCER PREVENTION RESEARCH, 2014, 7 (07) : 698 - 707
  • [2] Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
    Henneman, Linda
    van Miltenburg, Martine H.
    Michalak, Ewa M.
    Braumuller, Tanya M.
    Jaspers, Janneke E.
    Drenth, Anne Paulien
    de Korte-Grimmerink, Renske
    Gogola, Ewa
    Szuhai, Karoly
    Schlicker, Andreas
    Bin Ali, Rahmen
    Pritchard, Colin
    Huijbers, Ivo J.
    Berns, Anton
    Rottenberg, Sven
    Jonkers, Jos
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (27) : 8409 - 8414
  • [3] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
    Di Zhang
    Bijay Singh
    Jessica Moerland
    Owen Mitchell
    Lizbeth Lockwood
    Sarah Carapellucci
    Srinivas Sridhar
    Karen T. Liby
    Scientific Reports, 11
  • [4] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
    Zhang, Di
    Singh, Bijay
    Moerland, Jessica
    Mitchell, Owen
    Lockwood, Lizbeth
    Carapellucci, Sarah
    Sridhar, Srinivas
    Liby, Karen T.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model
    To, Ciric
    Williams, Charlotte R.
    Royce, Darlene B.
    Collins, Ryan M.
    Sporn, Michael B.
    Liby, Karen T.
    CANCER RESEARCH, 2014, 74 (19)
  • [6] FUNCTIONAL HETEROGENEITY OF ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA1-DEFICIENT CELLS
    Farkkila, Anniina
    Rodriquez, Alfredo
    Olkkonen, Jaana
    Sambel, Larissa
    Dominiquez, Julieta
    Joshi, Niraj
    Clairmont, Connor
    Zhou, Jia
    Lim, Kah-Suan
    Hautaniemi, Sampsa
    D'Andrea, Alan
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 204 - 204
  • [7] OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
    Baquero, Juan Miguel
    Marchena-Perea, Erik
    Mirabet, Rocio
    Torres-Ruiz, Raul
    Blanco-Aparicio, Carmen
    Rodriguez-Perales, Sandra
    Helleday, Thomas
    Benitez-Buelga, Carlos
    Benitez, Javier
    Osorio, Ana
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice
    van de Ven, Marieke
    van der Burg, Eline
    van der Gulden, Hanneke
    Klarenbeek, Sjoerd
    Bouwman, Peter
    Jonkers, Jos
    JOURNAL OF PATHOLOGY, 2017, 241 (04): : 511 - 521
  • [9] The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance
    Da Costa, Alexandre Andre B. A.
    Bose, Arindam
    Martignetti, David
    Ayala-Zambrano, Cecilia
    Ravindranathan, Ramya
    Sadatrezaei, Golbahar
    Jiao, Yuqing
    Kochupurakkal, Bose
    Nguyen, Huy
    Lazaro, Jean-Bernard
    Parmar, Kalindi
    Shapiro, Geoffrey I.
    D'Andrea, Alan D.
    CANCER RESEARCH, 2023, 83 (07)
  • [10] PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor.
    Ding, Liya
    Wang, Qiwei
    Kearns, Michael
    Jiang, Tao
    Konstantinopoulos, Panagiotis
    Matulonis, Ursula
    Zhao, Jean
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 23 - 23
12345